公开(公告)号：EP3263571A1

公开(公告)日：2018-01-03

申请号：EP17172002.2

申请日：2008-03-28

申请人： Progenics Pharmaceuticals, Inc. ,  Wyeth LLC (Formerly Known as Wyeth)

发明人： SMOLENSKAYA, Valeriya, N ,  AL-SHAREFFI, Kadum A. ,  PEREZ, Julio ,  SHAH, Syed M. ,  BOYD, Thomas

IPC分类号： C07D489/04 ,  A61K31/439 ,  A61P43/00

摘要： The present invention provides a new form of (R)-N-methylnaltrexone bromide, and compositions thereof, useful as a peripheral mu opiod receptor antagonist.

摘要翻译： 本发明提供了一种新的（R）-N-甲基纳曲酮溴化物及其组合物，可用作外周多巴胺受体拮抗剂。

公开(公告)号：EP2730578A1

公开(公告)日：2014-05-14

申请号：EP13189343.0

申请日：2008-02-06

申请人： Progenics Pharmaceuticals, Inc.

发明人： Avey, Alfred, A. ,  Perez, Julio

IPC分类号： C07D489/08 ,  G01N30/24

CPC分类号： C07D489/08 ,  G01N30/24

摘要： This invention relates to synthesis of (R),(R)2 , 2'-bis-MNTX, as shown in Formula (1), and related methods and products.

摘要翻译： 本发明涉及式（1）所示的（R），（R）2，2'-双-MNTX的合成及其相关方法和产物。

公开(公告)号：EP2558493A2

公开(公告)日：2013-02-20

申请号：EP11769680.7

申请日：2011-04-15

申请人： Progenics Pharmaceuticals, Inc.

发明人： MA, Dangshe ,  NAGASHIMA, Kirsten ,  KENNEDY, Brian ,  DONOVAN, Gerald, P. ,  KANG, Yun ,  OLSON, William, C. ,  KUMAR, Shankar ,  TSURUSHITA, Naoya ,  MAROZSAN, Andre, J. ,  CUPO, Albert

IPC分类号： C07K16/12 ,  C12N15/13 ,  A61K39/395 ,  A61P31/04

CPC分类号： C07K16/1282 ,  A61K39/40 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

摘要： Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen- binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.

公开(公告)号：EP2450360A2

公开(公告)日：2012-05-09

申请号：EP11180242.7

申请日：2006-05-25

申请人： Progenics Pharmaceuticals, Inc.

发明人： Wagoner, Howard ,  Sanghvi, Suketu. P ,  Boyd, Thomas. A ,  Verbicky, Christopher ,  Andruski, Stephen

IPC分类号： C07D489/08 ,  A61K31/485 ,  A61P1/12 ,  A61P25/04

CPC分类号： C07D489/08

摘要： This invention relates to S-MNTX, methods of producing S-MNTX, pharmaceutical preparations comprising S-MNTX and methods for their use.

摘要翻译： 本发明涉及S-MNTX，生产S-MNTX的方法，包含S-MNTX的药物制剂及其使用方法。

公开(公告)号：EP2240489A1

公开(公告)日：2010-10-20

申请号：EP08713403.7

申请日：2008-02-06

申请人： Progenics Pharmaceuticals, Inc.

发明人： AVEY, Alfred, A. ,  PEREZ, Julio

IPC分类号： C07D489/08

CPC分类号： C07D489/08 ,  G01N30/24

摘要： This invention relates to synthesis of (R),(R)-2,2' -bis-MNTX, as shown in Formula (I), and related methods and products.

公开(公告)号：EP2150817A1

公开(公告)日：2010-02-10

申请号：EP08767460.2

申请日：2008-04-30

申请人： Progenics Pharmaceuticals, Inc.

发明人： OLSON, William, C. ,  MADDON, Paul, J. ,  PEVEAR, Daniel, C. ,  ISRAEL, Robert, J. ,  MURGA, Jose, D.

IPC分类号： G01N33/53

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2812 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76

摘要： This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist. The viral load reducing dose results in a suppression of mean viral load by 1.0 log10 within about four days following administration of the CCR5 receptor antagonist, and suppression of viral load in the subject persists at or below a level of reduction of 1.0 log10 for about two to three weeks. This invention also provides a method of elevating CD4+ cell count in an HIV-1 -infected human subject which comprises administering to the subject at a predefined interval an effective HIV-1 viral load-reducing dose of a humanized antibody designated PRO 140, or an anti-CCR5 receptor monoclonal antibody.

公开(公告)号：EP2137191A2

公开(公告)日：2009-12-30

申请号：EP08742363.8

申请日：2008-03-28

申请人： Progenics Pharmaceuticals, Inc.

发明人： AVEY, Alfred, A. ,  PEREZ, Julio ,  DOSHAN, Harold, D. ,  CHANDRASEKARAN, Appavu ,  ROTSHTEYN, Yakov

IPC分类号： C07D489/04 ,  A61K31/439 ,  A61P43/00

CPC分类号： C07D489/08 ,  C07D489/04

摘要： The present invention provides a compound of formula I: wherein R1, R2, R2' and X' are as defined and described herein, methods of manufacture thereof and compositions thereof, useful for example as peripheral mu opioid receptor antagonists in treatment of side effects of opioid administration.

公开(公告)号：EP2101774A2

公开(公告)日：2009-09-23

申请号：EP07871566.1

申请日：2007-11-21

申请人： Progenics Pharmaceuticals, Inc.

发明人： PEREZ, Julio ,  HAN, Ami Qi ,  ROTSHTEYN, Yakov

IPC分类号： A61K31/485 ,  C07D489/02 ,  C07D489/06

CPC分类号： C07D489/08

摘要： Novel 7,8-saturated-4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the 7,8-saturated-4,5-epoxy-morphinanium analogs and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as modulators of opioid receptors.

公开(公告)号：EP2099456A2

公开(公告)日：2009-09-16

申请号：EP07871562.0

申请日：2007-11-21

申请人： Progenics Pharmaceuticals, Inc.

发明人： PEREZ, Julio ,  HAN, Ami Qi ,  KUMARAN, Govindaraj ,  ROTSHTEYN, Yakov

IPC分类号： A61K31/485 ,  C07D489/02 ,  C07D489/06

CPC分类号： A61K31/485 ,  C07D491/048

摘要： Novel N-oxides of 4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the N-oxides of 4,5-epoxy-morphinanium analogs and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as modulators of opioid receptors.

公开(公告)号：EP2040746A1

公开(公告)日：2009-04-01

申请号：EP07809720.1

申请日：2007-06-19

申请人： Progenics Pharmaceuticals, Inc. ,  Cornell Research Foundation, Inc.

发明人： OLSON, William C. ,  MADDON, Paul J. ,  FRANTI, Michael ,  IYER, Sai Prasad N. ,  KANG, Kenneth ,  MOORE, John P. ,  BEDDOWS, Simon

IPC分类号： A61K39/21 ,  A61K39/00 ,  A61K39/12 ,  C07K2/00 ,  C07K17/00 ,  C07K1/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2740/15022 ,  C12N2740/16122

摘要： This invention provides processes of purifying and recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof. Non-ionic detergent is used in the processes to obtain a purified trimer product, which is separated from aggregates. The process further comprises treating the preparation with a non-ionic detergent so as to thereby convert the high molecular weight aggregates into trimers, and purifying and recovering the trimers from the preparation so treated.

摘要翻译： 本发明提供了从包含逆转录病毒Env蛋白质三聚体和其高分子量聚集体的制剂中纯化和回收逆转录病毒包膜（Env）蛋白质的三聚体的方法。 在工艺中使用非离子型洗涤剂以获得纯化的三聚体产物，其从聚集体分离。 该方法还包括用非离子型去污剂处理制剂，从而将高分子量聚集体转化为三聚体，并从如此处理的制备物中纯化并回收三聚体。